Adderall News and Research RSS Feed - Adderall News and Research

Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

After marijuana and alcohol, the most commonly abused drugs by those over the age of 14 are prescription and over-the-counter medications. [More]
Shire announces acquisition of Meritage Pharma

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones. [More]
Shire announces completion of NPS Pharma acquisition

Shire announces completion of NPS Pharma acquisition

Shire plc announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals, Inc. and the subsequent acquisition of NPS Pharma. [More]
Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week. [More]
University of Copenhagen researchers move closer to developing antidote against cocaine addiction

University of Copenhagen researchers move closer to developing antidote against cocaine addiction

Researchers at the University of Copenhagen have gained new insight into the mechanism behind a protein dopamine transporter that could help in the development of future medical treatment against cocaine addiction. [More]
National survey shows decrease in alcohol, cigarette and illicit drug use among U.S. teens

National survey shows decrease in alcohol, cigarette and illicit drug use among U.S. teens

A national survey of students in U.S. middle schools and high schools shows some important improvements in levels of substance use. [More]
Mice may hold clues in development of ADHD, autism and bipolar disorder

Mice may hold clues in development of ADHD, autism and bipolar disorder

A darting mouse may hold an important clue in the development of Attention Deficit Hyperactivity Disorder (ADHD), autism and bipolar disorder, according to a study by a Vanderbilt University-led research team recently published in the Proceedings of the National Academy of Sciences. [More]
Shire receives FDA guidance on regulatory path for investigational compound SHP 465

Shire receives FDA guidance on regulatory path for investigational compound SHP 465

Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. [More]
Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II). [More]
Viewpoints: Wheaton injunction muddies court's ruling on contraceptives; Boston hospital merger problems; advice for new VA chief

Viewpoints: Wheaton injunction muddies court's ruling on contraceptives; Boston hospital merger problems; advice for new VA chief

In a bizarre attempt to have it both ways, the Supreme Court held that a small evangelical Protestant college in Illinois did not have to include contraceptive coverage in employee health insurance even though it didn't fill out the paperwork the government required for claiming an exemption. .. [More]
10,000 toddlers receive medication for ADHD, shows report

10,000 toddlers receive medication for ADHD, shows report

"It does not surprise me that some children are being given medicine as the easy way out but that doesn't mean it's the right way to do it," says Max Wiznitzer, MD, a pediatric neurologist at University Hospitals Rainbow Babies & Children's Hospitals about the Center for Disease Control's estimate 10,000 toddlers receive medication for attention-deficit/hyperactivity disorder (ADHD). [More]
Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work. [More]
Research findings point to potential biomarkers for early detection of at-risk youth

Research findings point to potential biomarkers for early detection of at-risk youth

Researchers at the University of California, San Diego School of Medicine have discovered impaired neuronal activity in the parts of the brain associated with anticipatory functioning among occasional 18- to 24-year-old users of stimulant drugs, such as cocaine, amphetamines and prescription drugs such as Adderall. [More]
Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Research roundup: Medicaid eligibility; tracking discontinued randomized trials; decline in work-based insurance

Under the Affordable Care Act (ACA), changes in income and family circumstances are likely to produce frequent transitions in eligibility for Medicaid and health insurance Marketplace coverage for low- and middle-income adults. [More]
Viewpoints: 'Middlling news' on enrollment; 'secret mandate exemption;' Obama's surprising appearance between two ferns

Viewpoints: 'Middlling news' on enrollment; 'secret mandate exemption;' Obama's surprising appearance between two ferns

By the beginning of the month, 4.2 million people had selected a plan. But that doesn't mean they have insurance. Reporters on a conference call asked about the number who had paid, and the administration's representatives said they don't know. [More]
Global initiatives underscore shire's long-term commitment to rare disease community

Global initiatives underscore shire's long-term commitment to rare disease community

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease Day and invites others to join them in its continued commitment to the rare disease community. [More]

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories, Inc. today reported fourth quarter and full year ended December 31, 2013 results. [More]

Shire signs agreement to supply authorized generic version of Adderall XR

Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR. [More]
State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

State highlights: Calif. Gov. Vetoes 'biosimilars' bill; health data gateway opens in Calif.; L.A. health workers required to get flu shots

A selection of health policy stories from California. A bill that would have allowed "biosimilar" drugs to be substituted for biologic drugs was vetoed over the weekend by Gov. Jerry Brown (D), who said it was premature to pass the law until the Federal Drug Administration has worked out standards for the new drugs. [More]
First Edition: October 16, 2013

First Edition: October 16, 2013

Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate. [More]